What happened, in summary

Elizabeth was 45 when she was diagnosed with stage 3 breast cancer after first finding a problem in November 2017. Her mother had developed breast cancer at 51, so the family had already been encouraged to remain alert. When an initial appointment was delayed until January 2018, Elizabeth was referred to another hospital for assessment. Her cancer was described as highly hormone-dependent. She approached the diagnosis with optimism and determination, focusing on reducing stress and protecting her hormonal balance. Treatment included breast-conserving surgery with a lumpectomy, chemotherapy, and radiation therapy. She also joined a clinical trial for an aromatase inhibitor. Elizabeth followed the plan on her doctor's recommendation and felt hopeful, relieved, and motivated. She did not report serious treatment side effects or major financial hardship. She later said she was in remission and no longer required treatment. Even so, the family history continued to shape her concerns for her sisters and their children, and she tried to live normally while remaining prepared to face cancer again if it returned.